These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

116 related articles for article (PubMed ID: 38165014)

  • 1. Prevalence, incidence, risk factors and residual risk associated with viral infections among eligible Brazilian blood donors.
    Santos APA; Rios DRA; Trindade CLC; Oliveira FEG; Oliveira MB; de Melo SN; Belo VS
    Transfus Med; 2024 Feb; 34(1):46-53. PubMed ID: 38165014
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Prevalence, incidence and residual risk of transfusion transmitted viruses (HBV, HCV and HIV infections) in Lithuanian blood donors from 2004 to 2018: The incidence/window-period model study.
    Grubyte S; Urboniene J; Nedzinskiene L; Jelinskaite A; Zagminas K; Ambrozaitis A; Jancoriene L
    PLoS One; 2021; 16(2):e0246704. PubMed ID: 33606700
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The risk of transmitting HCV, HBV or HIV by blood transfusion in Victoria.
    Whyte GS; Savoia HF
    Med J Aust; 1997 Jun; 166(11):584-6. PubMed ID: 9201178
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Residual risk of transfusion-transmitted infection with human immunodeficiency virus, hepatitis C virus, and hepatitis B virus in Korea from 2000 through 2010.
    Kim MJ; Park Q; Min HK; Kim HO
    BMC Infect Dis; 2012 Jul; 12():160. PubMed ID: 22817275
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The impact of nucleic acid testing to detect human immunodeficiency virus, hepatitis C virus, and hepatitis B virus yields from a single blood center in China with 10-years review.
    Wu D; Feng F; Wang X; Wang D; Hu Y; Yu Y; Huang J; Wang M; Dong J; Wu Y; Zhu H; Zhu F
    BMC Infect Dis; 2022 Mar; 22(1):279. PubMed ID: 35321684
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Evolution of residual risk for HIV, HCV and HBV, from 1999 to 2010, in blood donations of the Centro Hospitalar S. João, EPE, Porto, Portugal].
    Koch C; Araújo F
    Acta Med Port; 2013; 26(4):371-6. PubMed ID: 24016646
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Prevalence and trends of markers of hepatitis B virus, hepatitis C virus and human Immunodeficiency virus in Argentine blood donors.
    Flichman DM; Blejer JL; Livellara BI; Re VE; Bartoli S; Bustos JA; Ansola CP; Hidalgo S; Cerda ME; Levin AE; Huenul A; Riboldi V; Treviño EM; Salamone HJ; Nuñez FA; Fernández RJ; Reybaud JF; Campos RH
    BMC Infect Dis; 2014 Apr; 14():218. PubMed ID: 24755089
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Trends in prevalence, incidence, and residual risk of major transfusion-transmissible viral infections in United Arab Emirates blood donors: impact of individual-donation nucleic acid testing, 2004 through 2009.
    Al Shaer L; AbdulRahman M; John TJ; AlHashimi A
    Transfusion; 2012 Nov; 52(11):2300-9. PubMed ID: 22691239
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Incidence and estimated rates of residual risk for HIV, hepatitis C, hepatitis B and human T-cell lymphotropic viruses in blood donors in Canada, 1990-2000.
    Chiavetta JA; Escobar M; Newman A; He Y; Driezen P; Deeks S; Hone DE; O'Brien SF; Sher G
    CMAJ; 2003 Oct; 169(8):767-73. PubMed ID: 14557314
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Prevalence of hepatitis B virus, hepatitis C virus, and human immunodeficiency virus among blood donors of Mekelle blood bank, Northern Ethiopia: A three-year retrospective study.
    Degefa B; Gebreeyesus T; Gebremedhin Z; Melkamu G; Gebrekidan A; Hailekiros H; Tsegay E; Niguse S; Abdulkader M
    J Med Virol; 2018 Nov; 90(11):1724-1729. PubMed ID: 29905962
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Prevalence, incidence and residual risk of transfusion-transmitted HBV infection before and after the implementation of HBV-NAT in northern Brazil.
    Corrêa ASM; Lamarão LM; Vieira PCM; de Castro RBH; de Almeida NCC; de Castro JAA; de Lima MSM; Palmeira MK; Meireles ALLP; Burbano RR
    PLoS One; 2018; 13(12):e0208414. PubMed ID: 30566494
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Seroprevalence of transfusion transmissible viral infections (HIV, HBV and HCV) among voluntary blood donors at University of Gondar Comprehensive Specialized Hospital, Gondar; Northwest Ethiopia.
    Tigabu A; Engda T; Mekonnen F
    BMC Infect Dis; 2019 May; 19(1):393. PubMed ID: 31068138
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Impact of individual-donation nucleic acid testing on risk of human immunodeficiency virus, hepatitis B virus, and hepatitis C virus transmission by blood transfusion in South Africa.
    Vermeulen M; Lelie N; Sykes W; Crookes R; Swanevelder J; Gaggia L; Le Roux M; Kuun E; Gulube S; Reddy R
    Transfusion; 2009 Jun; 49(6):1115-25. PubMed ID: 19309474
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Estimating window period blood donations for human immunodeficiency virus Type 1, hepatitis C virus, and hepatitis B virus by nucleic acid amplification testing in Southern Pakistan.
    Moiz B; Moatter T; Shaikh U; Adil S; Ali N; Mahar F; Shamsuddin N; Khurshid M
    Transfusion; 2014 Jun; 54(6):1652-9. PubMed ID: 24383918
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Impact of nucleic acid testing for hepatitis B virus, hepatitis C virus, and human immunodeficiency virus on the safety of blood supply in Italy: a 6-year survey.
    Velati C; Romanò L; Fomiatti L; Baruffi L; Zanetti AR;
    Transfusion; 2008 Oct; 48(10):2205-13. PubMed ID: 18631163
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Safe blood in the absence of viral infections due to HBV, HCV and HIV in serological window period in donors].
    Contreras AM; Reta CB; Torres O; Celis A; Domínguez J
    Salud Publica Mex; 2011; 53 Suppl 1():S13-8. PubMed ID: 21877067
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Estimation of the risk of hepatitis B virus, hepatitis C virus and human immunodeficiency virus infectious donations entering the blood supply in England, 1993-2001.
    Soldan K; Barbara JA; Ramsay ME; Hall AJ
    Vox Sang; 2003 May; 84(4):274-86. PubMed ID: 12757501
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Residual risk of transfusion-transmitted human immunodeficiency virus, hepatitis C virus, and hepatitis B virus infections in Italy.
    Gonzalez M; Règine V; Piccinini V; Vulcano F; Giampaolo A; Hassan HJ
    Transfusion; 2005 Oct; 45(10):1670-5. PubMed ID: 16181219
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Prevalence, incidence and residual risk of transfusion-transmitted hepatitis C virus and human immunodeficiency virus after the implementation of nucleic acid testing in Italy: a 7-year (2009-2015) survey.
    Velati C; Romanò L; Piccinini V; Marano G; Catalano L; Pupella S; Facco G; Pati I; Tosti ME; Vaglio S; Grazzini G; Zanetti A; Liumbruno GM
    Blood Transfus; 2018 Sep; 16(5):422-432. PubMed ID: 30036178
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Trends in residual risk of transfusion-transmitted viral infections (HIV, HCV, HBV) in France between 1992 and 2002 and impact of viral genome screening (Nucleic Acid Testing)].
    Pillonel J; Laperche S; ; ;
    Transfus Clin Biol; 2004 Apr; 11(2):81-6. PubMed ID: 15120104
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.